{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:05:00Z","timestamp":1780099500482,"version":"3.54.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1038\/nrclinonc.2009.160","type":"journal-article","created":{"date-parts":[[2009,11,28]],"date-time":"2009-11-28T01:42:21Z","timestamp":1259372541000},"page":"680-682","source":"Crossref","is-referenced-by-count":3,"title":["Dasatinib regimens for patients with chronic myeloid leukemia"],"prefix":"10.1038","volume":"6","author":[{"given":"Fran\u00e7ois","family":"Guilhot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrclinonc2009160_CR1","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz, M.  et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase: results of a phase 2 study. Blood 99, 1928\u20131937 (2002).","journal-title":"Blood"},{"key":"BFnrclinonc2009160_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz, M.  et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemia. N. Engl. J. Med. 354, 2531\u20132541 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc2009160_CR3","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","volume":"113","author":"H Kantarjian","year":"2009","unstructured":"Kantarjian, H.  et al. Phase 3 study of dasatinib 140 mg once daily versus twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15 months median follow-up. Blood 113, 6322\u20136329 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc2009160_CR4","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","volume":"109","author":"F Guilhot","year":"2007","unstructured":"Guilhot, F.  et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase. Blood 109, 4143\u20134150 (2007).","journal-title":"Blood"},{"key":"BFnrclinonc2009160_CR5","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","volume":"109","author":"A Hochhaus","year":"2006","unstructured":"Hochhaus, A.  et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109, 2303\u20132309 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc2009160_CR6","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","volume":"109","author":"J Cortes","year":"2006","unstructured":"Cortes, J.  et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis. Blood 109, 3207\u20133213 (2006).","journal-title":"Blood"},{"key":"BFnrclinonc2009160_CR7","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Alfonso Quint\u00e1s-Cardama","year":"2007","unstructured":"Alfonso Quint\u00e1s-Cardama, A.  et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J. Clin. Oncol. 25, 3908\u20133914 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc2009160_CR8","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","volume":"111","author":"P Le Coutre","year":"2008","unstructured":"Le Coutre, P.  et al. Nilotinib (formerly AMN 107), a highly selective BCR-ABL tyrosine kinase inhibitor, is a active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia. Blood 111, 1834\u20131839 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc2009160_CR9","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah, N. P.  et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improved tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 26, 3204\u20133212 (2008).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.160","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:02:36Z","timestamp":1684468956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2009.160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":9,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["BFnrclinonc2009160"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2009.160","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}